| Name | Title | Contact Details |
|---|
Oakbridge Insurance is a prominent independent insurance and risk management agency with over 100 years of experience. Founded with a mission to enhance the insurance industry through community-focused service, Oakbridge combines the flexibility of an independent agency with the resources of a larger brokerage. As of 2023, it operates under Audax Private Equity, providing a range of commercial and personal insurance solutions. The company specializes in commercial property and casualty insurance, employee benefits, surety bonds, personal property and casualty insurance, and risk management services. Oakbridge operates through a partnership model, having expanded from four founding agencies to 13 partner firms by 2022, employing 280 people. The agency fosters a collaborative culture, emphasizing trust and long-term relationships with clients. In 2022, Oakbridge was recognized as a Top 100 Property/Casualty Agency by *Insurance Journal*, highlighting its strong position in the industry.
IMCD Group is a global distributor of specialty chemicals and ingredients, headquartered in Rotterdam, Netherlands. Founded in 1995, the company is listed on the Amsterdam stock exchange and celebrated its 25th anniversary in 2020. IMCD specializes in serving various industries, including pharmaceuticals, food, personal care, coatings, and lubricants, providing formulatory solutions tailored to customer needs. The company has expanded its operations internationally, with significant growth in the Americas, including the establishment of IMCD US in 2015. IMCD Group generates approximately $4.7 billion in revenue and employs around 3,570 people worldwide. Known for its innovative approach and minimal corporate bureaucracy, IMCD maintains strong partnerships with a diverse range of suppliers and customers, from small manufacturers to large corporations.
Diamond Baseball Holdings (DBH) is a New York-based company founded in 2021 that owns and operates a significant portfolio of Minor League Baseball (MiLB) clubs affiliated with Major League Baseball. The company focuses on professional management, best practices, and innovative investments to enhance fan experiences, brand engagement, player conditions, and community impact. As of 2024, DBH has acquired 33 teams, making it one of the largest ownership groups in MiLB history. The company emphasizes maintaining baseballs traditions while upgrading facilities and improving player welfare. DBH operates as part of Silver Lakes sports investments and applies private equity strategies to enhance operations and achieve market-beating returns. Its initiatives include partnerships for stadium upgrades and innovations aimed at boosting fan attendance and creating superior environments for both fans and players.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.